Document is current
Any future updates will be listed below
-
Authors
Oreja-Guevara, Celia https://orcid.org/0000-0002-9221-5716
Potra, Stanca
Bauer, Birgit https://orcid.org/0000-0002-2475-2042
Centonze, Diego https://orcid.org/0000-0002-8390-8545
Giambastiani, Maria-Paz https://orcid.org/0000-0003-2628-6687
Giovannoni, Gavin https://orcid.org/0000-0001-9995-1700
Kesselring, Jϋrg https://orcid.org/0000-0002-8645-7364
Langdon, Dawn https://orcid.org/0000-0003-1128-7417
Morrow, Sarah https://orcid.org/0000-0001-7522-6440
Nouvet-Gire, Jocelyne
Pontaga, Maija
Rieckmann, Peter https://orcid.org/0000-0001-6921-0135
Schippling, Sven https://orcid.org/0000-0002-6804-1795
Alexandri, Nektaria https://orcid.org/0000-0002-9806-8358
Shanahan, Jane
Thompson, Heidi
van Galen, Pieter https://orcid.org/0000-0001-7074-2550
Vermersch, Patrick https://orcid.org/0000-0003-0997-8817
Yeandle, David
-
Funding
Funding for this research was provided by:
Merck KGaA
- License Information
-
More Information
Article History
Received: 6 February 2023
Accepted: 4 August 2023
First Online: 9 October 2023
Declarations
:
: <b>Celia Oreja-Guevara</b> has received honoraria from Biogen Idec, Novartis, Sanofi Genzyme, Almirall, the healthcare business of Merck KGaA, Darmstadt, Germany. <b>Diego Centonze</b> is an advisory board member of Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Sanofi-Genzyme, Teva and has received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, anofi-Genzyme, Teva. He is also the principal investigator in clinical trials for Bayer Schering, Biogen, the healthcare business of Merck KGaA, Darmstadt, Germany, Mitsubishi, Novartis, Roche, Sanofi-Genzyme, Teva. His preclinical and clinical research was supported by grants from Bayer Schering, Biogen Idec, Celgene, the healthcare business of Merck KGaA, Darmstadt, Germany, Novartis, Roche, Sanofi-Genzyme, Teva. <b>Gavin Giovannoni</b> has received compensation for serving as a consultant or speaker for or has received research support from AbbVie, Aslan, Atara Bio, Biogen, BMS-Celgene, GlaxoSmithKline, Janssens/J&J, Japanese Tobacco, Jazz Pharmaceuticals, LifNano, Merck & Co, Kenilworth, NJ, the healthcare business of Merck KGaA, Darmstadt, Germany/EMD Serono, Moderna, Novartis, Sanofi and Roche/Genentech. <b>Sven Schippling</b> receives research grants from US EMD Serono. <b>Pieter van Galen</b> has received honoraria from the healthcare business of Merck KGaA, Darmstadt, Germanyfor MS in the 21st Century activities, and has received consulting and speaking fees from Johnson & Johnson, Novartis, Merck N.V.-S.A., Overijse, Belgium, an affiliate of KGaA, Darmstadt, Germany, Celgene R&D Sarl, F. Hoffman-La Roche, NV Roche SA, Mylan GMBH and Excemed.
: This article is based on findings from previous studies and a debate; it does not report any new studies with human participants or animals performed by any of the authors.
